Hanna Kim, PhD

Counsel
Norton Rose Fulbright US LLP
hanna.kim@nortonrosefulbright.com
Hanna
Kim
Hanna Kim, PhD
San Francisco
Suite 1050
One Embarcadero Center
San Francisco
California
94111
United States
+1 628 231 6805

Hanna Kim focuses her practice on patent prosecution, due diligence counselling and strategic portfolio development and management, primarily for clients in the biotech, pharmaceutical and medical technology industries.

Hanna has extensive experience prosecuting and advising on technologies involving therapeutics, including biologics and small- and macro-molecule drugs; immunology technologies such as antibodies, CAR-T and related platforms; CRISPR and other gene-editing technologies; cancer diagnostics and therapies; single cell assays and sequencing technologies; nanoparticle-based drug delivery systems and a broad range of diagnostic innovations. Hanna also regularly advises on and prosecutes complex life sciences inventions that incorporate AI and machine learning components.

Hanna’s experience includes preparing and prosecuting patent applications in the United States and various foreign jurisdictions; developing and managing patent portfolios for companies ranging from early-stage startups to large multinational corporations, as well as for universities; and conducting various due diligence, including freedom-to-operate, invalidity, patent landscape and patentability analyses. She has also supported patent portfolio evaluations in connection with IPOs and venture financings, including Series A and Series B rounds.

Hanna is registered to practice before the United States Patent and Trademark Office (USPTO).

Representative experience

  • Managed a patent portfolio that was licensed for a total value of US$500 million.
  • Evaluated patent portfolios for Series B financings that raised approximately US$170 million and US$200 million.
  • Provided support for a patent litigation matter that was settled for approximately US$1 billion.
  • Provided patent invalidity analysis for a biotech company valued at US$1.2 billion.
  • Cases with large‑molecule therapeutic technologies, including gene therapy platforms employing nano‑ and micro‑particle delivery systems such as lipid‑based and viral particles, as well as gene‑editing technologies including CRISPR, zinc finger nucleases (ZFNs) and TALENs.
  • Cases with protein and peptide‑based biologics, including antibodies and antibody fragments and variants, CAR‑T and TCR‑based immunotherapies, therapeutic polypeptides and small peptides, antigen and neoantigen‑based vaccines and diagnostics, single‑cell and proteomics‑driven technologies, recombinant nucleic acids (including siRNA) and aptamer platforms, as well as experience with antibody portfolios, including programs licensed to industry partners. Extensive experience handling immunology and stem cell cases.
  • Tissue engineering, siRNA delivery, nanoparticle formulations and cell encapsulations during doctoral-level training.
  • Cases relating to nanoparticle formulations.
  • Cases relating to stem cell manufacturing.
  • Diagnostic technologies, including nucleic acid‑ and biomarker‑based diagnostics involving DNA and RNA, genomics, transcriptomics and proteomics, as well as protein biomarker diagnostics and single‑cell‑based diagnostic and analytical platforms.
  • Cases relating to advanced research instrumentation and analytical platforms, including single‑cell genomics and barcoded sequencing technologies, expression library generation tools, antibody‑based research systems, cell‑profiling diagnostics and computational and AI/ML‑driven target identification methods.
  • Cases relating to digital health and AI/ML‑enabled technologies, including computational approaches for identifying biological targets, optimizing the design of biologics and small molecules, AI‑driven personalized treatment platforms and neuromodulation technologies.
  • Cases relating to medical device technologies, including devices and systems for the treatment of cardiovascular and heart‑related conditions.

Education

  • JD, UC Berkeley School of Law
  • PhD, MIT, Biomedical Engineering
  • BS and MA, summa cum laude, UCLA, Molecular, Cell and Developmental Biology

Admissions

  • California State Bar
  • US Patent and Trademark Attorney

Publications

  • Author, “Patenting AI/ML Life Sciences and TechBio Innovations - How Much Disclosure Is Sufficient?,” Intellectual Property & Technology Law Journal 37(6), June 2025

Membership and activities

  • California Lawyers Association
  • Asian Pacific American Bar Association Silicon Valley
  • American Intellectual Property Law Association
  • National Association of Women Lawyers
Bio